Sermorelin Therapy in United States (USA)

Sermorelin therapy rarely produces the dramatic before-and-after that patients picture when they walk into a clinic. It produces a slope. The first three weeks adjust sleep architecture and reduce the morning fog that comes with shallow stage-3 NREM. Somewhere between weeks four and twelve, a fasting IGF-1 draw confirms that the pituitary has actually responded to the nightly stimulus. By month three, the changes are visible in clothing fit, recovery between training sessions, and the joint stiffness that used to follow a long workday. Anyone who frames sermorelin as an injection rather than a multi-month endocrine protocol misses the part that determines whether the therapy works at all.

The protocol itself is unglamorous. A subcutaneous dose around bedtime, five nights on and two nights off, weekly self-assessment, a comprehensive metabolic panel and IGF-1 draw at twelve weeks, dose titration based on that lab data, and another check at six months. The compounded vial does the pharmacology. The schedule and the lab work do the medicine. Sites that focus only on the act of injecting or only on the telehealth intake skip the part where a patient and a prescriber sit with twelve weeks of numbers and decide whether to stay at 300 micrograms, move to 500, or extend the titration to receptor saturation around 750. That conversation is the therapy.

How the molecule asks the pituitary to do its job

Sermorelin is the first twenty-nine amino acids of endogenous growth hormone-releasing hormone. The native hypothalamic peptide is forty-four residues long, but cleavage and substitution work in the 1980s established that the 1-29 fragment carries the full intrinsic activity of GHRH at its receptor. Compounding pharmacies produce it as the acetate salt, lyophilized in single-patient vials and reconstituted with bacteriostatic water before subcutaneous administration.

The pharmacology is short to describe and important to understand. Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs, a Gs-coupled receptor that activates adenylyl cyclase, raises intracellular cyclic AMP, and triggers a pulse of stored growth hormone into the systemic circulation. Because the signal is upstream of the pituitary rather than a bolus of exogenous GH, the resulting release is pulsatile, time-limited, and still subject to negative feedback from somatostatin and from circulating IGF-1. This is the structural reason sermorelin does not produce the supraphysiologic GH peaks and the suppressed feedback loops associated with recombinant human growth hormone.

Two practical consequences follow. First, dosing at the wrong circadian window wastes most of the dose, because the somatotroph response is gated by the body’s own diurnal rhythm. The late-evening window, when somatostatin tone falls and natural GH release peaks during early slow-wave sleep, is the only point in the day where the pituitary is primed to answer. Second, the ceiling on the response is set by the somatotroph reserve, not by the dose. A pituitary with poor reserve will not produce a meaningful pulse regardless of how much sermorelin is administered, which is why baseline IGF-1 and, in unclear cases, a stimulation test matter before therapy begins.

Dosing schedule and titration curve

Clinical practice has converged on a relatively narrow dosing window. Most adults begin at 200 to 300 micrograms administered subcutaneously roughly thirty minutes before sleep, in the 10 p.m. to midnight window. The injection site rotates between the abdomen and the outer thigh. The dose is given five consecutive nights followed by a two-night washout, a schedule that limits receptor downregulation and preserves the responsiveness of the somatotroph population over months of therapy. Continuous nightly dosing without the washout works for short courses but tends to blunt the response curve by the second or third month.

Titration is weekly, not nightly. The standard upward step is 100 to 200 micrograms at a time, made on the basis of subjective sleep quality, morning alertness, and absence of side effects such as injection-site flushing, transient headache, or vivid dreaming severe enough to disrupt the night. Most adults settle into a maintenance range of 500 to 1000 micrograms, with the receptor-saturation plateau falling between 500 and 750 micrograms in the majority of patients. Doses below 150 micrograms rarely move IGF-1 in a clinically meaningful way and are essentially subtherapeutic regardless of how a patient feels on them.

Above the saturation point, the marginal yield falls sharply. A patient at 750 micrograms who pushes to 1000 may see a small additional IGF-1 movement, but the more common outcome is the same lab number with a higher injection cost and a slightly higher rate of paresthesia or mild edema. Pushing past 1000 micrograms is rarely justified and is usually a sign that either the diagnosis or the dosing window is wrong. A non-responder at 1000 micrograms is far more likely to have a pituitary problem than a dose problem.

The schedule survives travel, shift work, and missed nights. A skipped dose is not made up the next morning; the next scheduled bedtime dose is taken at the usual time. The vial, once reconstituted, is refrigerated and discarded after the timeframe stated on the compounded label, generally fourteen to thirty days depending on the preservative and the prescriber’s protocol. These are small operational details, but they decide whether a six-month course delivers six months of pharmacology or three.

What the lab work actually tracks across 12 weeks

The first formal lab draw is at week twelve. By that point, the somatotroph axis has had enough nights of stimulation to settle into its new steady state, and any genuine signal will be present in serum IGF-1. The panel pulled at twelve weeks is consistent across most reputable protocols: IGF-1, fasting glucose, hemoglobin A1c, and a comprehensive metabolic panel. Some prescribers add fasting insulin and a lipid panel to track insulin sensitivity directly.

IGF-1 is the headline number. A therapeutic response is typically a thirty to fifty percent increase from a documented baseline, landing the patient in the upper half of the age-adjusted reference range rather than chasing a number for its own sake. Moving an IGF-1 from the bottom decile of the range into the upper third is a successful course; pushing an already mid-range IGF-1 into the top five percent is not the goal and brings the same metabolic concerns that limit recombinant GH.

Fasting glucose and A1c track the one pharmacologic liability that matters in this class. Growth hormone is counter-regulatory to insulin, and any sustained increase in GH and IGF-1 can nudge fasting glucose upward and reduce peripheral insulin sensitivity. A pre-diabetic patient whose fasting glucose climbs from 98 to 112 at twelve weeks needs a dose discussion before a six-month renewal. The CMP catches the rarer issues, including changes in liver enzymes, electrolyte shifts, and renal markers, which are uncommon but worth knowing before they accumulate.

Timeline of subjective and measurable changes

Weeks one and two are usually quiet. Some patients report deeper sleep within the first ten nights, but most notice nothing specific. The early window is for establishing the injection routine, not for tracking outcomes.

Between week three and week six, the subjective effects begin. Sleep onset shortens, slow-wave sleep lengthens, and the morning wake feels less effortful. Energy in the late afternoon improves, often before any change in body composition. This is the period where adherence either holds or collapses, because the patient is paying for and injecting a peptide whose visible effects have not yet arrived.

Between week four and week twelve, IGF-1 moves. The magnitude varies with baseline, age, and somatotroph reserve, but the directional signal is reliable in a responder. The twelve-week labs confirm or deny that the pharmacology is working as intended and set the dose for the next quarter.

By month three, body composition changes become measurable. The pattern is consistent across cohorts: a modest reduction in visceral adiposity, a small increase in lean mass that requires resistance training to materialize, improved recovery between training sessions, and a reduction in low-grade joint stiffness. Libido and skin quality improve more variably and tend to track sleep quality more closely than IGF-1. By month six, the curve flattens, and continued therapy is a maintenance decision rather than a continued improvement decision.

Who responds and who doesn’t

The screening process matters because the contraindications are specific and the off-target risks are concentrated in a small group of patients. Active malignancy is an absolute contraindication, because elevating GH and IGF-1 across an intact pituitary axis can theoretically support residual or occult tumor proliferation, particularly in hormone-sensitive cancers. A recent cancer history is a conversation with an oncologist, not a checkbox on an intake form.

Severe or proliferative diabetic retinopathy is the second hard stop, because GH-mediated changes in retinal vasculature can accelerate disease that is already on a trajectory. Patients in the post-surgical critical-illness window or with acute respiratory failure should not be started on a GH secretagogue until the acute phase resolves. A non-functional pituitary, whether from prior tumor, radiation, or congenital deficiency, makes sermorelin pharmacologically pointless; those patients need recombinant GH, not an upstream stimulus to a gland that cannot respond.

Outside those groups, the typical candidate is an adult with age-appropriate decline in GH pulse amplitude, a baseline IGF-1 in the lower half of the reference range, intact glucose handling, and concrete goals around sleep, recovery, and body composition that can be measured at twelve weeks and at six months.

Sermorelin therapy is prescribed and dispensed through licensed providers and 503A or 503B compounding pharmacies operating under state and federal oversight, and the specifics of access, monitoring, and follow-up vary by jurisdiction. The directory below is organized by state and metro area so that the protocol described here can be matched to a local prescriber, a local lab for the twelve-week panel, and a compounding pharmacy familiar with the dosing and storage requirements that determine whether the next six months deliver the slope this therapy is designed to produce.

Mechanism, in plain words

Natural growth hormone is released by the pituitary in short overnight pulses. With age, the size and frequency of these pulses fall. Output at 55 looks nothing like output at 25. Most of the visible age signals associated with growth hormone decline, from softer sleep to slower healing to gradual fat redistribution, follow from that drop.

Sermorelin asks the pituitary to do its old job. It binds the same receptor that natural GHRH binds, and triggers the same release. Because the body's negative feedback loop remains in place, sermorelin cannot push growth hormone past the body's own safety ceiling. This is the structural reason it is generally considered safer than injected synthetic HGH.

What it is not

Sermorelin is not anabolic in the way testosterone is anabolic. It is not a fat loss drug. It is not a performance enhancer, and is not legally prescribed for that purpose. It is not a substitute for sleep, training, or protein. It is also not a quick result. The body needs months to fully translate restored GH pulses into measurable change.

The standard protocol

A first cycle generally runs 12 weeks, with a follow-up IGF-1 lab drawn at the end. Doses are dialed by the prescribing clinician based on baseline labs, body weight, and tolerance. The most common pattern in current US telehealth practice looks like this.

1. Intake and baseline labHealth questionnaire on energy, sleep, recovery, training, sexual function. Baseline IGF-1, fasting glucose, complete metabolic panel, lipid panel.
2. Clinician reviewA licensed clinician confirms medical appropriateness. If not appropriate, the consultation is refunded. If appropriate, dose is calculated.
3. DispensingCompounded sermorelin acetate is mailed from a 503A or 503B partner pharmacy with insulin syringes, alcohol pads, sharps container.
4. Self-administrationSingle subcutaneous injection at night, on an empty stomach. Standard schedule, five nights on and two nights off. Twelve weeks.
5. ReassessmentFollow-up IGF-1 at week 12. Dose held, raised, lowered, or paused based on labs and self-reported response.